We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Mindray Showcases Hematology Innovations at ISLH 2022

By LabMedica International staff writers
Posted on 27 Sep 2022
Print article
Image: The MC-80 digital cell morphology analyzer can screen and diagnose malignant and non-malignant blood diseases (Photo courtesy of Mindray)
Image: The MC-80 digital cell morphology analyzer can screen and diagnose malignant and non-malignant blood diseases (Photo courtesy of Mindray)

Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations in Laboratory Hematology (ISLH 2022) held between September 8-10 in Bologna, Italy. Held annually, the symposium serves as an international platform where the latest technology, new ideas and research findings in laboratory hematology are showcased and shared.

At ISLH 2022, Mindray held a seminar titled "The New Era of Digital Morphology", where Prof. Gina Zini and Prof. Anna Merino, two renowned experts in morphology, presented an evaluation of the performance of its MC-80 digital cell morphology analyzer in detecting onco-hematological diseases by referring to special clinical cases, and how it can help doctors screen and diagnose malignant and non-malignant blood diseases, respectively through high-resolution blood cell images. During the ISLH poster session, 32 posters from Mindray's hematology end-users were presented after stringent evaluation based on unique insights and exceptional academic values, outnumbering all other exhibitors. At its ISLH 2022 booth, Mindray showcased its new MC-80 digital cell morphology analyzer and the BC-700 series hematology analyzer, which attracted much interest from visitors. Mindray's academic strength was also recognized by the ISLH committee which granted the company the "Berend Houwen Travel Award" for outstanding contributions to the industry and excellence in academics.

Before ISLH, Mindray attracted over 700 participants to the HemaTalk Italy 2022 Global Live Event. Dr. Ramon Simon-Lopez from Mindray IVD Scientific Research and Medical Affairs, noted that the company has been utilizing its global resources to build a learning and exchange platform for global medical experts and empower the future of laboratory medicine. The attendees held an online conversation with Mindray’s R&D team to discuss the future of laboratory hematology and the latest trends in translating clinical research results into practice. A Q&A session followed where the attendees had their most important questions answered by Mindray’s experts.

Related Links:
Mindray 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.